|
Originally published In Press as doi:10.1074/jbc.M107285200 on November 13, 2001
J. Biol. Chem., Vol. 277, Issue 6, 4152-4158, February 8, 2002
Clotrimazole Binds to Heme and Enhances
Heme-dependent Hemolysis
PROPOSED ANTIMALARIAL MECHANISM OF CLOTRIMAZOLE*
Nguyen Tien
Huy,
Kaeko
Kamei ,
Takushi
Yamamoto,
Yoshiro
Kondo,
Kenji
Kanaori,
Ryo
Takano,
Kunihiko
Tajima, and
Saburo
Hara
From the Department of Applied Biology, Kyoto Institute of
Technology, Matsugasaki, Sakyo-ku, Kyoto 606-8585, Japan
Received for publication, July 31, 2001, and in revised form, October 4, 2001
 |
ABSTRACT |
Two recent studies have demonstrated that
clotrimazole, a potent antifungal agent, inhibits the growth of
chloroquine-resistant strains of the malaria parasite, Plasmodium
falciparum, in vitro. We explored the mechanism of
antimalarial activity of clotrimazole in relation to hemoglobin
catabolism in the malaria parasite. Because free heme produced from
hemoglobin catabolism is highly toxic to the malaria parasite, the
parasite protects itself by polymerizing heme into insoluble nontoxic
hemozoin or by decomposing heme coupled to reduced glutathione.
We have shown that clotrimazole has a high binding affinity for heme in
aqueous 40% dimethyl sulfoxide solution (association equilibrium
constant: Ka = 6.54 × 108
M 2). Even in water, clotrimazole formed a
stable and soluble complex with heme and suppressed its aggregation.
The results of optical absorption spectroscopy and electron spin
resonance spectroscopy revealed that the heme-clotrimazole complex
assumes a ferric low spin state (S = 1/2), having two
nitrogenous ligands derived from the imidazole moieties of two
clotrimazole molecules. Furthermore, we found that the formation of
heme-clotrimazole complexes protects heme from degradation by reduced
glutathione, and the complex damages the cell membrane more than free
heme. The results described herein indicate that the antimalarial
activity of clotrimazole might be due to a disturbance of hemoglobin
catabolism in the malaria parasite.
 |
INTRODUCTION |
Malaria has become a key global threat due to quickly spreading
resistance to quinoline-based antimalarial drugs such as quinine, chloroquine (CQ),1 and
mefloquine (1). Furthermore, artemisinin-resistant strains of
Plasmodium falciparum have been developed in the laboratory (2). Therefore, there has been extensive research into a new series of
antimalarial drugs. The antifungal agent clotrimazole (CLT) (Fig.
1) inhibits the growth of
chloroquine-resistant P. falciparum strains in
vitro (3, 4).
Mechanisms of the antimalarial activity of CLT have been proposed in
relation to Ca2+ ions; CLT inhibits the sarcoplasmic
reticulum Ca2+ pump and capacitative Ca2+
channels of malaria-infected red blood cells, causing the depletion of
intracellular Ca2+ stores (5, 6). Depletion of
intracellular Ca2+ induces the activation of protein kinase
R and phosphorylation of eukaryotic translation initiation factor 2 ,
thereby inhibiting protein synthesis in the parasite (7). However, the
actual mechanism of CLT antimalarial action at the molecular level
remains equivocal.
During development and proliferation in human erythrocytes, malaria
degrades hemoglobin to use as a major source of amino acids,
accompanied by the release of free heme. As free heme is highly toxic
to the malarial parasite, the parasite has developed a means of
detoxifying heme through polymerization to non-toxic, insoluble
hemozoin (8) or by degradation with GSH (9-11), which is found
at millimolar concentrations in red blood cells and parasite compartments (12, 13). About 30-50% of free heme is detoxified by
polymerization at the trophozoite stage (10, 14, 15), and the remainder
is detoxified by GSH-dependent degradation. The two
detoxification processes of free heme are initiated by heme
histidine-rich protein (HRP) 2 and heme-GSH complex formation, respectively. Antimalarials such as quinine and CQ also bind to free
heme and inhibit its degradation. Furthermore, the imidazole moiety of
CLT behaves as an axial ligand, binding free heme. We therefore
considered that CLT exerts antimalarial activity by forming complexes
with heme, similar to the heme-binding antimalarials, CQ and quinine.
In this study, the coordination reaction between CLT and heme was
investigated by optical absorption spectroscopy and electron spin
resonance (ESR) spectroscopy. The structure of the heme-CLT complex was
characterized based on spectroscopic evidence. Furthermore, we compared
the effects of CLT and CQ on GSH-dependent heme degradation and heme-induced hemolysis, and we propose a mechanism of antimalarial CLT action.
 |
EXPERIMENTAL PROCEDURES |
Materials--
GSH, CLT, CQ, imidazole, and hemin (heme)
were from Sigma. Mesoheme was from Porphyrin Products Inc.
(Logan, UT). Human blood was drawn from healthy volunteers. Dimethyl
sulfoxide (Me2SO) was purchased from Wako Pure
Chemicals (Osaka, Japan). All other chemicals were of the highest
commercially available grade.
Heme Preparation--
At the start of each experiment, a stock
heme solution was prepared by dissolving hemin chloride in 20 mM NaOH and then removing the remaining hemin crystals by
centrifugation for 10 min at 15,000 rpm. The heme concentration was
estimated from absorbance at 385 nm ( mM = 58,400) in 100 mM NaOH (16) and adjusted to 1.0 mM. This stock reagent was stored in the dark on ice and
used within 24 h.
Absorption Spectra--
All absorption spectra were recorded on
a Hitachi U-3300 double-beam spectrophotometer (Tokyo, Japan) using a
1.0-cm light-path quartz cuvette at 23 °C. A solution of 17 µM heme in 40% Me2SO and 20 mM
HEPES buffer (pH 7.4) revealed Soret at 401 nm and Q band absorption
maxima at 493 and 616 nm, and the ratio of absorption of the Soret (401 nm) and Q band (616 nm) was 28.72, indicating that the heme in the
present system exists as a monomeric mode (17-19). The optical
absorption spectra of the heme-CLT and heme-imidazole complexes were
recorded 5 min after adding CLT (final concentration, 100 µM) and imidazole (final concentration, 500 µM) to heme (final concentration, 17 µM) in
40% Me2SO buffered with 20 mM HEPES (pH 7.4).
The total volume of the reaction mixture was 1.0 ml.
Spectrometric Titration--
Differential absorption spectra
were measured on a Hitachi U-3300 spectrophotometer as follows. The
drug, CLT or CQ, was added sequentially to a sample cuvette containing
heme solution. The reference compartment held two cuvettes, one
containing an identical heme solution aliquot to which a buffer other
than the drug was added and the other containing a solution without
heme and the same amount of the drug.
In the case of CLT titration, both the sample cuvette and the first
reference cuvette contained 17 µM heme in 40%
Me2SO buffered by 20 mM HEPES (pH 7.4), and the
second reference cuvette contained the same solution without heme.
Increasing amounts of CLT (0 µM-105.6 µM
in 6.6 µM increments) in Me2SO were titrated
with the contents of the sample cuvette and the second reference
cuvette, in which the total volume of the reaction mixture was
maintained at 1.0 ml.
Before adding CQ, the sample cuvette and the first reference cuvette
contained 5 µM heme in 40% Me2SO buffered by
20 mM HEPES (pH 7.4), and the second reference cuvette
contained the same solution without heme. During the titration of
heme-CQ complex formation, increasing amounts of CQ (0-36
µM in 4 µM increments) were added to both
the sample and the second reference cuvettes, where the total volume of
the reaction mixture was 1.0 ml during the titration. All
differential spectra were recorded at wavelengths between 350 and 700 nm, and the concentrations of heme-CLT and heme-CQ complexes were
evaluated based on absorbance at 416 and 401 nm, respectively.
The binding mode of CLT and CQ to heme was analyzed in terms of Hill
(20, 21) and Scatchard (22, 23) plots. The equilibrium association
constants for the formation of heme-CLT and heme-CQ complexes, as well
as the number of ligands that bind to heme, were calculated from
Hill plots using Eq. 1,
|
(Eq. 1)
|
and analyzed using the standard equation (Eq. 2),
|
(Eq. 2)
|
where A0, A ,
and A are the absorbance of the initial, final, and mixed
species, respectively; H represents heme; L is
the ligand (CLT or CQ); n is the number of ligand molecules that bind to heme; and Ka is the equilibrium
association constant of the heme-ligand complex.
ESR Measurements of Heme-CLT Complexes--
ESR measurements
were continued for heme-CLT complexes that were formed in
Me2SO at molar ratios of heme to CLT of 1:1, 1:1.5, 1:2,
1:4, and 1:8. After an overnight incubation at room temperature, the
ESR spectrum of heme-CLT complex was recorded at 4.2 K by a JES-TE 300 spectrometer with 100-kHz field modulation. The integrated frequency
counter monitored the microwave frequency of each measurement. The
magnetic field strength was calibrated by hyperfine splitting of Mn(II)
ion (8.69 milliteslas (mT)) doped in MgO powder. Powdered lithium-tetracyanoquinodimethane radical (g = 2.0025) was
used as the standard g value. The ESR data were analyzed and calibrated using a Winrad system (Radical Research Inc., Tokyo). The typical conditions for ESR measurements were as follows: microwave power, 6.0 milliwatts; modulation magnitude, 0.68 mT; sweep range 30 mT to 500 mT;
sweep time, 4 min; and time constants, 0.1 s.
GSH-dependent Heme Degradation and Its Inhibition by
CLT or CQ--
Heme degradation by GSH was monitored by measuring
spectral change as described by Atamna and Ginsburg (9). Fresh GSH
stock solution (200 mM) was prepared in isotonic standard
buffer (50 mM sodium phosphate containing 68 mM
NaCl, 4.8 mM KCl, and 1.2 mM MgSO4,
pH 7.4) (24, 25). Heme (final concentration, 3 µM) and
GSH (final concentration, 2 mM) were mixed in isotonic
standard buffer (pH 7.4) and incubated at 37 °C. Absorption spectra
(300-600 nm) were recorded at 6-min intervals after mixing, using the
same spectrophotometer. The rate constant and t1/2 of GSH-dependent heme degradation in the absence of CLT and
CQ were calculated from the decrease of absorbance at 365 nm in terms of first-order reaction kinetics.
In the presence of CLT (6 µM) or CQ (6 µM),
the time-dependent spectral measurements were obtained by
the same procedure. CLT in Me2SO and CQ in HEPES buffer
(200 mM, pH 7.4) were all prepared as 3 mM
stock solutions. Heme (3 µM), GSH (2 mM), and either CLT or CQ (6 µM) were mixed in 0.2 M
HEPES buffer (pH 7.4) and incubated at 37 °C. In the control
experiment, Me2SO (final concentration, 0.2% (v/v)) was
added to the mixture of heme (3 µM) and GSH (2 mM) instead of CLT and CQ. The time-dependent
change of absorbance at 396 nm was recorded as an indicator of heme degradation.
Hemolysis--
Fresh blood from healthy donors was heparinized
(1 mg of heparin/ml blood) to suppress clotting. The erythrocytes were
separated from plasma by centrifugation at 1,500 × g
for 3 min and washed six times with isotonic standard buffer.
Thereafter, the effects of CLT and CQ on hemolysis induced by heme were
examined in 0.5% cell suspensions in isotonic standard buffer.
Erythrocyte suspensions (0.6 ml) were shaken with various
concentrations of heme (0-20 µM) and CLT or CQ (0, 1, 5, and 10 µM) at 37 °C for 150 min at 140 cycles/min.
Intact erythrocytes were then removed by centrifugation at 1,500 × g for 3 min, and the amount of hemoglobin released from
the hemolyzed erythrocytes into the supernatant was determined by
measuring absorbance at 578 nm (26). After the pelleted intact erythrocytes were lysed with water and centrifuged to obtain the supernatant, the hemoglobin content in intact erythrocytes was measured
as absorbance at 578 nm. The degree of hemolysis was calculated from
the ratio of hemoglobin content released from erythrocytes hemolyzed by
heme to the total heme content of the erythrocytes (26).
When using heme-bound erythrocytes, 0.5% of red blood cells in
isotonic standard buffer, pH 7.4, were incubated with 10 µM heme at room temperature for 10 min. The erythrocyte
suspension was separated by centrifugation at 1,500 × g for 3 min, and the pellet was washed three times with
isotonic standard buffer to remove free heme, thus providing heme-bound
erythrocytes. A sample of 0.6 ml of a 0.5% suspension of heme-bound
erythrocytes was prepared in isotonic standard buffer,
Me2SO (1%), CLT (10 µM), CQ (10 µM), or GSH (2.5 mM) was then added, and the
mixture was incubated at 37 °C for 2 h. The hemolysis degree
was calculated from three such experiments.
 |
RESULTS |
Absorption Spectrum of Heme Complexed with CLT--
Fig.
2, curve 1, shows Soret and Q
band absorption at 401, 493, and 616 nm by heme (17 µM) in 40% Me2SO, which is characteristic of
high spin ferric complexes assuming a five-coordinate structure (27,
28) with weak axial ligand such as water or chloride anion. When excess
CLT (final concentration, 100 µM) was added to the
mixture, the Soret shifted toward red wavelengths at 412 nm, and Q band
absorption was evident at 536 and 560 nm, as shown in Fig. 2,
curve 2. The observed spectrum was classified into a
six-coordinate ferric complex having nitrogenous ligands at both axial
positions. In fact, the spectroscopic properties coincided with those
of similar solutions of heme and imidazole (Soret, 410 nm; Q bands, 535 and 560 nm) shown in Fig. 2, curve 3. Furthermore, heme-bis-imidazole complexes have similar spectra (29, 30), as
summarized in Table I. These results
support the notion that CLT, like imidazole, has affinity for
the heme chromophore. It is likely that the imidazole moiety of CLT is
the nitrogenous donor.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Absorption spectra of heme, heme-imidazole
complex, and heme-CLT complex. Absorption spectra were measured in
40% Me2SO buffered by 20 mM HEPES, pH 7.4, and
recorded after a 5-min mixing of heme and ligand when no further
spectral change was observed. Curve 1, heme alone;
curve 2, heme-imidazole complex (mixture of 0.5 mM imidazole and 17 µM heme); curve
3, heme-CLT complex (mixture of 100 µM CLT and 17 µM heme). Left y axis, Soret region;
right y axis, Q region.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Absorption maxima for protoheme (ferric protoporphyrin IX) complexed
with CLT, CQ, imidazole, N-methylimidazole, or hexapeptide containing
two histidine residues
|
|
The heme-CLT complex in the absence of Me2SO gave a similar
absorption spectrum, as indicated by a Soret band at 416 nm and Q bands
at 533 and 564 nm (Table I). In contrast, the spectrum of the
heme-imidazole complex in the absence of Me2SO included a
broad peak at 433 nm (data not shown), which is derived mainly from the
aggregated form of heme (31, 32). The heme-CLT complex, prepared in
HEPES buffer in the absence of Me2SO, was quite stable under ambient conditions. The values of the absorption maxima of the
heme-CLT complex in Me2SO and in HEPES buffer did not vary significantly, and heme precipitation was undetectable even in HEPES
buffer. These results provide potent evidence of the ability of CLT to
stabilize the monomeric form of heme and to inhibit the formation of
polymeric heme in aqueous solution.
Spectrophotometric Heme Titration--
To characterize the binding
of heme with CLT, spectrophotometric heme titration was performed by
measuring the differential spectra between heme and heme-CLT complex at
various CLT concentrations. As described under "Experimental
Procedures," aqueous-Me2SO (40% v/v) buffered by 20 mM HEPES buffer, pH 7.4, was used because heme in this
solution should form a monomer at concentrations up to 26.6 µM (17-19). Fig.
3A shows that CLT perturbs the
spectrum of heme, indicating interaction between the drug and heme.
Continuous addition of CLT into a heme solution achieves conversion of
the heme spectrum to a form with lower Soret molar absorption and a
Soret maximum shifted to a longer wavelength. The absorption spectra
changed as the CLT concentration increased, through isosbestic points
at 409, 467, 514, and 585 nm, indicating that only two absorbing
species are present in the reaction mixture. During heme-CQ
complex formation, the spectrum change was accompanied by a significant
decrease in the intensity of monomeric heme at the Soret and Q bands
(Fig. 3B), as described by Egan et al. (19), indicating interaction between CQ and heme.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Titration of the heme-CLT
(A) and heme-CQ (B) interaction.
Differential spectral titration of drugs with heme proceeded as
described under "Experimental Procedures." Concentration of CLT
(A) was increased from 0 µM to 105.6 µM in 6.6 µM increments, and concentration
of CQ (B) was increased from 0 µM to 36 µM in increments of 4 µM. Arrows
indicate the effect of increasing the concentration of CLT and
CQ.
|
|
The effects of heme interactions with CLT and CQ on titration behavior
were analyzed using Hill plots (20, 21) to determine the number of
molecules bound to heme in aqueous Me2SO. Hill plots of our
binding data in Fig. 4 show heme-CLT
complexes at 17 µM heme and heme-CQ complexes at 5 µM heme. The slopes of these linear graphs are 2 and 1, respectively, within experimental error.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 4.
Hill plots of heme-CLT ( ) and heme-CQ
( ) association. The pH and the temperature were constant at pH
7.4 and 22 °C. The n values correspond to individual
slopes. , heme-CLT association at 17 µM heme in which
absorbance was monitored at 416 nm. The n and
Ka values were 2.03 and 6.54 × 108
M 2, respectively. , heme-CQ interaction at
5 µM heme in which absorbance was monitored at 401 nm.
The n and Ka values were 1.06 and
1.71 × 105 M 1,
respectively.
|
|
The same data are presented in Scatchard plots in Fig.
5 (22, 23). The straight line
indicates the absence of cooperative interaction between heme and CQ,
whereas a curved graph is observed for heme-CLT complex, indicating
cooperation and the involvement of non-identical interacting binding
sites. The analysis using the Hill plot demonstrates that heme binds
two CLT molecules with an association constant (Ka)
of 6.54 × 108 M 2, whereas
heme binds one molecule of CQ with a Ka of 1.71 × 105 M 1 in aqueous 40%
Me2SO at pH 7.4.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 5.
Scatchard plots of heme-CLT association ( )
at 17 µM heme and of heme-CQ association ( )
at 5 µM heme. Conditions were
similar to those described in the legend to Fig. 4. indicates
[Ao A/Ao A ]. The unit of /[Ligand] is 1 × 104 M 1 for heme-CLT complex
and 1 × 106 M 1 for heme-CQ
complex.
|
|
ESR Spectrum of Heme-CLT Complex--
We further clarified the
electronic and coordination structures of the heme-CLT complex
by ESR spectroscopy. We recorded ESR spectra at 4.2 K for heme-CLT
complexes prepared in Me2SO, as described under
"Experimental Procedures." Before adding CLT, the observed ESR
spectrum (Fig. 6, curve 1) of
heme (0.5 mM) contained the line and g values (g = 6 and g = 2.0) typical of the ferric high spin (S = )
species, taking five-coordinate geometry into account (33). A weak
signal is always observed at about g = 4.3, which may be due to
non-heme iron from decomposed heme (34) or impurities in the sample
tube and Dewar assembly. On adding CLT (final concentration, 100 mM) to the reaction mixture, the ESR signal intensity of
the high spin species decreased significantly with the concomitant
formation of a new paramagnetic species with a distorted rhombic ESR
line (Fig. 6, curves 2 and 3; g1 = 1.46, g2 = 2.26, and g3 = 2.98), which was
characteristic of ferric low spin complex (S = 1/2) having
strong axial ligands at both axial positions. Upon the further addition
of CLT, the molar ratio of CLT/heme reached 8, and the ESR signal of
the new species was recorded exclusively, suggesting that CLT tended to
shift the equilibrium to form the low spin ferric species (data not
shown). The observed ESR shape of the low spin species line was quite similar to that recorded for a frozen mixture of heme-imidazole complex
(data not shown). In addition, the observed g values of those complexes
agreed well (e.g. protoheme-imidazole and
protoheme-hexapeptide complex) (Table
II). This provided experimental evidence
that both complexes, heme-CLT and heme-imidazole complexes, have
similar ligands at the axial positions.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
ESR spectrometric titration performed by
changing mixing molar ratios of mesoheme and CLT in
Me2SO. Spectrum of mesoheme (0.5 mM): curve 1, before addition of CLT;
curve 2, after addition of a 1.5-fold excess of CLT;
curve 3, after adding 4-fold excess of CLT. +, weak ESR
signal appearing at g = 4.3, which would be assigned as a non-heme
type iron complex or impurities; *, ghost cavity. Li-TCNQ,
lithium-tetracyanoquinodimethane radical.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
The g values and crystal field parameters (calculated by using Bohan's
proposal (37)) of heme-CLT complex and relating ferric low-spin
complexes
|
|
Inhibition of GSH-dependent Heme Degradation by
CLT--
The absorption spectrum of heme in HEPES buffer (200 mM, pH 7.4) exhibited two Soret bands at 385 and 342 nm,
representing the monomer and dimer form, respectively (Fig.
7) (35), whereas the spectrum of heme in
40% Me2SO revealed only one Soret band at 401 nm,
indicating the monomer form of heme (Fig. 2) (17-19). The maximal
absorption of the Soret of heme (3 µM) was shifted to 365 nm after adding GSH (2 mM) as described in Ref. 9, probably due to the formation of GSH-heme complex. Fig. 7 shows that the Soret
absorption of heme complexed with GSH declined rapidly as described in
Ref. 9, indicating the degradation of heme by GSH. The rate constant
and t1/2 of the heme degradation were calculated
from fitting to the first-order reaction as 4.5 × 10 4 s 1 and 1,540 s, respectively, in
isotonic standard buffer at pH 7.4.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 7.
Heme degradation by GSH. Heme (3 µM) in isotonic buffer was mixed with 2 mM
GSH and incubated at 37 °C. Absorption spectra (300-600 nm) were
measured at 6-min intervals immediately (six upper lines)
and at 1 and 2 h (two lower lines) after mixing.
Broken line, absorption spectrum of heme (3 µM). Inset, absorbance at 365 nm was regressed
against time to fit first-order reaction.
|
|
The absorption spectra of heme-CLT and of heme-CQ complexes did not
change upon the addition of GSH, indicating that neither complex
interacted with GSH (data not shown). The GSH-dependent degradation of heme (3 µM) in the presence of CLT (6 µM) or CQ (6 µM) was monitored as a
decrease of absorbance at 396 nm because heme-CLT complex and heme-CQ
complex have similar molecular absorption coefficients at 396 nm. The
results shown in Fig. 8 indicate that CLT
and CQ inhibit GSH-dependent heme degradation.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 8.
GSH-dependent heme degradation in
presence of CLT and CQ. Heme (3 µM) and GSH (2 mM) were mixed in 0.2 M HEPES buffer (pH 7.4)
in the absence ( ) and presence of CLT ( , 6 µM), CQ
( , 6 µM), or Me2SO ( , 0.2% v/v).
GSH-dependent heme degradation was monitored by changes in
absorbance at 396 nm.
|
|
Effect of CLT on Erythrocyte Hemolysis Induced by
Heme--
Hemolysis experiments were performed using fresh blood cells
as described under "Experimental Procedures." Up to only 2.5% hemolysis occurred in controls in which no heme was added. The hemolysis induced by the presence of heme was potentiated by CLT as
well as by CQ (Fig. 9A), and
the effects depended on the concentrations of both heme and the added
agents. We also observed that CLT alone at up to 20 µM
had no effect on hemolysis in the absence of heme (data not shown).
Therefore, the enhancement of heme-dependent hemolysis of
erythrocytes may be caused by the formation of heme-CLT complex. The
amount of heme-dependent hemolysis enhanced by CQ was
almost identical to that observed in a previous study (36).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 9.
Potentiation of heme-dependent
hemolysis by CLT and CQ. Hemolysis of erythrocytes was monitored
by measuring hemoglobin absorbance at 578 nm. Percent of hemolysis was
calculated from the ratio of hemoglobin content released from
erythrocytes hemolyzed by heme to the total heme content of
erythrocytes as described under "Experimental Procedures."
A, suspensions of erythrocytes were incubated for 2.5 h
without (+) or with 1 µM ( , ), 5 µM
( , ), and 10 µM ( , ) agents; then, the degree
of hemolysis was measured. Closed and open
symbols indicate CLT and CQ, respectively. B,
suspensions of erythrocytes were incubated with 1.5 µM
heme and 10 µM CLT or 10 µM CQ at 37 °C
for 150 min; then, the degree of hemolysis was measured.
|
|
The similar enhancement of heme-dependent hemolysis by CLT
and CQ indicates that they have the same potential at high
concentrations of heme (5-20 µM), as shown in Fig.
9A. However, at lower heme concentration (1.5 µM), CLT was more effective than CQ (Fig.
9B).
To understand this potency of CLT in greater detail, we treated
erythrocytes with 10 µM heme followed by
sedimentation and then washing the sample three times. The erythrocytes
recovered in this manner were regarded as heme-bound intact
erythrocytes that were not hemolyzed by heme but which had membranes
bound to heme (9). These erythrocytes were incubated with CLT or CQ to
determine the effect of these drugs on the susceptibility of
erythrocytes to hemolysis. Fig. 10
shows that CLT but not CQ increased the hemolysis of heme-bound
erythrocytes, whereas Me2SO and GSH had no effect.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 10.
Effects of CLT and CQ on hemolysis of
heme-bound erythrocytes. Me2SO (DMSO)
(1%), CLT (10 µM), CQ (10 µM), or GSH (2.5 mM) was added to heme-bound erythrocyte suspensions and
incubated at 37 °C for 2 h. Hemolysis rate was calculated from
three experiments as described under "Experimental
Procedures."
|
|
 |
DISCUSSION |
We propose a mechanism for the antimalarial activity of CLT based
on the results of spectroscopic and physiological measurements. We
investigated interactions occurring between heme and CLT using optical
absorption and electron spin resonance. The observed optical and ESR
parameters of the heme-CLT complex (Tables I and II) were compared with
those of related complexes to assign the axial ligand of the complex.
The ESR and optical absorption spectra indicated six-coordinate
complexes having nitrogenous ligands at both axial positions of heme,
as has frequently been observed for naturally occurring heme enzymes
and synthetic iron porphyrin complexes (29, 30). For example,
spectroscopic parameters of cytochrome b-559 indicate that
the heme chromophore has two histidine moieties at both axial positions
(29). In addition, the spectroscopic parameters of heme-CLT and
heme-imidazole complexes agree closely. This suggests that the
imidazole moiety of CLT is likely to be the axial ligand of the complex.
The crystal field parameters, rhombicity (|R/µ|) and
tetragonality (|µ/ |), of the heme-CLT complex and related
complexes were calculated in terms of Bohan's proposal (37). The
calculated crystal field parameters of heme-CLT complexes agree well
with those of heme-imidazole complexes, as summarized in Table II. On
the basis of the results obtained from ESR and optical measurements, as
well as from the crystal field calculation, we concluded that the axial
ligand of the heme-CLT complex is therefore the nitrogenous donor
derived from the imidazole moiety of CLT (Fig. 1).
The proposed coordination structure of heme-CLT complex is consistent
with the results of the Hill plot in that the heme-CLT complex bears
two molecules of CLT at both axial positions. The equilibrium
association constant (Ka) for the formation of the
heme-CLT complex was 6.54 × 108
M 2. In comparison with the
Ka values of heme-imidazole derivatives (38), CLT is
one of the strongest axial ligands for heme. We presently cannot
explain why CLT has pronounced affinity for heme under our reaction
conditions. However, the hydrophobic group of CLT, three aromatic rings
with a chlorine atom, should stabilize axial ligation to heme. Taking
into account the results of the Hill and Scatchard plots, we found that
CLT forms a stable six-coordinate iron porphyrin complex with a high
equilibrium association constant.
The malaria parasite has developed processes to detoxify free
heme released as a result of hemoglobin catabolism. Some of the free
heme (30-50%) is subsequently polymerized to non-toxic hemozoin (3)
through the formation of complex with malarial HRP. The
remaining non-polymerized free heme passes through the membrane of food
vacuoles and also reaches the cytosol of the parasite (39-42), where
free heme may be efficiently decomposed by reaction with GSH (10, 11).
It is reported that oral CLT (single dose of 1 g) was absorbed
rather efficiently, reaching a concentration in plasma of 2 µM within 2-4 h of administration (43) without serious
side effects, and easily diffused into erythrocytes (43, 44).
Therefore, CLT should be able to reach the parasite compartment,
enabling production of stable heme-CLT complexes in both erythrocytes
and parasites.
On the addition of GSH to heme, the Soret absorption blue-shifted to
365 nm due to the formation of heme-GSH intermediate complexes, and the
GSH-dependent heme degradation proceeded quickly (Fig. 7).
On the contrary, GSH caused no spectral variation in the heme-CLT
complex (Table I), and the Soret absorption of the complex remained
unchanged (Fig. 8). Thus, the axial-ligated CLT completely inhibited
GSH-dependent heme degradation. The concentration of GSH in
red blood cells and in the parasite compartment reaches millimolar
levels (12, 13). Nevertheless, the high equilibrium association
constant of CLT (6.54 × 108
M 2) should allow the heme-CLT complex to
exist in the erythrocyte and malaria parasite.
Furthermore, free heme, which would otherwise bind to malarial HRP
initiating heme polymerization into non-toxic hemozoin, is also changed
to heme-CLT complex through the axial ligand exchange reaction caused
by minimal amounts of CLT in vitro. The ESR spectrum due to
heme-CLT complex was recorded after a minimal addition of CLT to a
solution of the heme-HRP model peptide (27 amino acids) complex in
which two histidine residues are bound at the axial position (data not
shown). This means that the heme, including heme bound to HRP, can be
easily converted to heme-CLT complex in the presence of CLT. These
findings indicate that the formation of heme-CLT complex considerably
affects malarial defense systems against toxic free heme, heme
polymerization by HRP, and heme decomposition by GSH.
Taking into account the molecular structure of CLT, the heme-CLT
complex in which two CLT molecules bind to both axial positions is
considered to be hydrophobic and bulky. The hydrophobic and bulky
species tend to localize in the hydrophobic layer of the membrane,
destabilizing its bilayer structure. Comparing the hemolysis that
proceeds in the absence and presence of CLT, we found that the free
heme-dependent hemolysis was effectively facilitated by the
ligation of CLT to free heme (Figs. 8 and 9). The hydrophobicity and
the molecular size of the heme-CLT complex may therefore be important
factors for hemolysis. When the population of heme-CLT complexes
becomes critical, malaria-infected erythrocytes are expected be
hemolyzed, causing the malarial parasites to die. In addition, heme-CLT
complexes accumulating in the malarial membrane may destroy the
membrane, fatally damaging the malaria parasite. Furthermore, CLT was
found to be more effective than CQ in promoting hemolysis (Fig. 9). The
Hill plots shown in Fig. 4 indicate that CQ has higher affinity to heme
than does CLT with an ~10-fold lower concentration of CQ required for
half saturation in 40% Me2SO solution. Therefore, we are
unable to explain why CLT demonstrated a higher ability to promote
hemolysis. However, in other work, we found that the
concentrations of CLT and CQ required for half saturation for binding
with 10 µM heme were around 10 µM and
nearly identical in 0.2 M HEPES, pH 7.4, containing 1 mg/ml
bovine serum albumin.2 This
result indicates that CLT has high affinity to heme similar to CQ under
physiological conditions. Thus, the difference in the effects of
hemolysis between CLT and CQ might have arisen due to the difference of
hydrophobicity and structure of these complexes with heme but not due
to a difference in the affinity to heme. In addition, we have also
found that CLT promotes intracellular heme-induced
hemolysis.3 We have found
that CLT (5 µM) enhances hemolysis from 8 to 60% in
cases in which free heme had been released from hemoglobin inside
erythrocytes by pretreatment with menadione.2 Based on
these results and the fact that CLT has the ability to compete with HRP
and GSH, we expect that CLT at clinically achievable concentrations in
plasma would invade erythrocytes and parasites, form a complex with
heme released from hemoglobin, and damage cell membranes. The
decomposition of the membrane triggered by the heme-CLT complex is
thought to play an important role in the antimalarial action of
CLT.
One proposal states that 2-chlorophenyl-bis-phenyl methanol, one of
several in vivo metabolites of CLT lacking the imidazole, has weaker antimalarial activity (50% growth inhibitory concentration (IC50) of ~11 µM) than CLT
(IC50 of ~1 µM) (3). This indicates that
the imidazole group is not essential but is involved in the antimalarial activity of CLT. The antimalarial mechanism of
2-chlorophenyl-bis-phenyl methanol might be due to inhibition of the
Ca2+ pump and Ca2+ channels (5, 6, 43).
However, the much higher antimalarial activity of CLT than of
2-chlorophenyl-bis-phenyl methanol might be caused by the formation of
complexes with heme through an imidazole group, supporting our theory
of the antimalarial mechanism of CLT involving malarial heme catabolism.
Previous reports (3, 4) indicate that CLT inhibits the growth of
CQ-resistant strains of malaria. Furthermore, the low IC50
value of CLT against malaria makes it a practical antimalarial drug
because a plasma CLT concentration of 2 µM is achievable with an oral dose of 1 g. Therefore, CLT is promising as a new antimalarial drug.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Applied
Biology, Kyoto Institute of Technology, Matsugasaki, Sakyo-ku, Kyoto
606-8585; Japan. Tel.: 81-75-724-7553; Fax: 81-75-724-7532; E-mail:
kame@ipc.kit.ac.jp.
Published, JBC Papers in Press, November 13, 2001, DOI 10.1074/jbc.M107285200
3
N. T. Huy, K. Kamei, R. Takano, and
S. Hara, submitted for publication.
2
Unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
CQ, chloroquine;
CLT, clotrimazole;
ESR, electron spin resonance;
HRP, histidine-rich protein 2;
heme or protoheme, ferric protoporphyrin IX;
mesoheme, mesoprotoporphyrin IX.
 |
REFERENCES |
| 1.
|
Trigg, P. I.,
and Kondrachine, A. V.
(1998)
in
Malaria: Parasite Biology, Pathogenesis, and Protection
(Sherman, I. W., ed)
, pp. 11-22, ASM press (American Society for Microbiology), Washington, D. C.
|
| 2.
|
Inselburg, J.
(1985)
Am. J. Trop. Med. Hyg.
34,
417-418
|
| 3.
|
Saliba, K. J.,
and Kirk, K.
(1998)
Trans. R. Soc. Trop. Med. Hyg.
92,
666-667[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Tiffert, T.,
Ginsburg, H.,
Krugliak, M.,
Elford, C.,
and Lew, V. L.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
331-336[Abstract/Free Full Text]
|
| 5.
|
Benzaquen, L. R.,
Brugnara, C.,
Byers, H. R.,
Gattoni-Celli, S.,
and Halperin, J. A.
(1995)
Nat. Med.
1,
534-540[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Tiffert, T.,
Staines, H. M.,
Ellory, J. C.,
and Lew, V. L.
(2000)
J. Physiol.
525 (1),
125-134[Abstract/Free Full Text]
|
| 7.
|
Aktas, H.,
Fluckiger, R.,
Acosta, J. A.,
Salvage, J. M.,
Palakurthi, S. S.,
and Halperin, J. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8280-8285[Abstract/Free Full Text]
|
| 8.
|
Francis, S. E.,
Sullivan, D. J.,
and Goldberg, D. E.
(1997)
Annu. Rev. Microbiol.
51,
97-123[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Atamna, H.,
and Ginsburg, H.
(1995)
J. Biol. Chem.
270,
24876-24883[Abstract/Free Full Text]
|
| 10.
|
Ginsburg, H.,
Famin, O.,
Zhang, J.,
and Krugliak, M.
(1998)
Biochem. Pharmacol.
56,
1305-1313[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Platel, D. F. N.,
Mangou, F.,
and Tribouley-Duret, J.
(1999)
Mol. Biochem. Parasitol.
98,
215-223[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Atamna, H.,
and Ginsburg, H.
(1997)
Eur. J. Biochem.
250,
670-679[Medline]
[Order article via Infotrieve]
|
| 13.
|
Luersen, K.,
Walter, R. D.,
and Muller, S.
(2000)
Biochem. J.
346,
545-552
|
| 14.
|
Wood, P. A.,
and Eton, J. W.
(1993)
Am. J. Trop. Med. Hyg.
48,
465-472
|
| 15.
|
Slater, A. F. G.
(1993)
Pharmacol. Ther.
57,
203-235[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Shaklai, N.,
Shviro, Y.,
Rabizadeh, E.,
and Kirschner-Zilber, I.
(1985)
Biochim. Biophys. Acta
821,
355-366[Medline]
[Order article via Infotrieve]
|
| 17.
|
Beaven, G. H.,
Chen, S.,
D'Albis, A.,
and Gratm, W. B.
(1974)
Eur. J. Biochem.
41,
539-546[Medline]
[Order article via Infotrieve]
|
| 18.
|
Collier, G. S.,
Pratt, J. M., De,
Wet, R.,
and Tshabalala, C. F.
(1979)
Biochem. J.
179,
281-289[Medline]
[Order article via Infotrieve]
|
| 19.
|
Egan, T. J.,
Mavuso, W. W.,
Ross, D. C.,
and Marques, H. M.
(1997)
J. Inorg. Biochem.
68,
137-145[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Van Holde, K. E.
(1971)
Physical Biochemistry
, pp. 62-64, Prentice Hall, Englewood Cliffs, NJ
|
| 21.
|
Brault, D.,
and Rougee, M.
(1974)
Biochem. Biophys. Res. Commun.
57,
654-659[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Scatchard, G.
(1949)
Ann. N. Y. Acad. Sci.
51,
660-672[CrossRef]
|
| 23.
|
Cantor, C. R.,
and Schimmel, P. R.
(1980)
Biophysical Chemistry, Part III
, pp. 849-863, W. H. Freeman, San Francisco, CA
|
| 24.
|
Chou, A. C.,
Chevli, R.,
and Fitch, C. D.
(1980)
Biochemistry
19,
1543-1549[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Fitch, C. D.,
Chevli, R.,
and Gonzalex, Y.
(1974)
Antimicrob. Agents Chemother.
6,
757-762[Abstract/Free Full Text]
|
| 26.
|
Shviro, Y.,
and Shaklai, N.
(1987)
Biochem. Pharmacol.
36,
3801-3807[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Kaminsky, L. S.,
Byrne, M.,
and Davison, A. J.
(1972)
Arch. Biochem. Biophys.
150,
355-361[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Pasternack, R. F.,
Gillies, B. S.,
and Stahlbush, J. R.
(1978)
J. Am. Chem. Soc.
100,
2613-2619[CrossRef]
|
| 29.
|
Babcock, G. T.,
Widger, W. R.,
Cramer, W. A.,
Oerling, W. A.,
and Metz, J. G.
(1985)
Biochemistry
24,
3638-3645[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Katagiri, M.,
Tsutsui, K.,
Yamano, T.,
Shimonishi, Y.,
and Ishibashi, F.
(1987)
Biochem. Biophys. Res. Commun.
149,
1070-1076[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Gallagher, W. A.,
and Elliotte, W. B.
(1968)
Biochem. J.
108,
131-136[Medline]
[Order article via Infotrieve]
|
| 32.
|
Campbell, V. M.
(1981)
Studies on Hemin and Cobalt Corrinoids in Aqueous SolutionPh.D. thesis
, University of Witwaterstrand
|
| 33.
|
Momenteau, M.
(1973)
Biochim. Biophys. Acta
304,
814-827[Medline]
[Order article via Infotrieve]
|
| 34.
|
Tajima, K.
(1989)
Inorg. Chim. Acta
163,
115-122[CrossRef]
|
| 35.
|
Sahini, V. E.,
Dumitrescu, M.,
Volanschi, E.,
Birla, L.,
and Diaconu, C.
(1996)
Biophys. Chem.
58,
245-253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Dutta, P.,
and Fitch, C. D.
(1983)
J. Pharmacol. Exp. Ther.
225,
729-734[Abstract/Free Full Text]
|
| 37.
|
Bohan, T. L.
(1977)
J. Magn. Reson.
26,
109-118
|
| 38.
|
Kadish, K. M.,
Smith, K. M.,
and Guilard, R.
(2000)
The Porphyrin Handbook
, Vol. 9
, pp. 221-419, Academic Press, Orlando, FL
|
| 39.
|
Cannon, J. B.,
Kuo, F.,
Pasternack, R. F.,
Wong, N. M.,
and Muller-Eberhard, U.
(1984)
Biochemistry
23,
3715-3721[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Rose, M. Y.,
Thompson, R. A.,
Light, R. W.,
and Olson, J. S.
(1985)
J. Biol. Chem.
260,
6632-6640[Abstract/Free Full Text]
|
| 41.
|
Ginsburg, H.,
and Demel, R. A.
(1983)
Biochim. Biophys. Acta
732,
316-319[Medline]
[Order article via Infotrieve]
|
| 42.
|
Ginsburg, H.,
and Demel, R. A.
(1984)
Chem. Phys. Lipids
35,
331-347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Brugnara, C.,
Armsby, C. C.,
Sakamoto, M.,
Rifai, N.,
Alper, S. L.,
and Platt, O.
(1995)
J. Pharmacol. Exp. Ther.
273,
266-272[Abstract/Free Full Text]
|
| 44.
|
Brugnara, C.,
Gee, B.,
Armsby, C. C.,
Kurth, S.,
Sakamoto, M.,
Rifai, N.,
Alper, L.,
and Platt, O. S.
(1996)
J. Clin. Invest.
97,
1227-1234[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. T. Huy, K. Mizunuma, K. Kaur, N. T. T. Nhien, M. Jain, D. T. Uyen, S. Harada, R. Jain, and K. Kamei
2-tert-Butyl-8-Quinolinamines Exhibit Potent Blood Schizontocidal Antimalarial Activity via Inhibition of Heme Crystallization
Antimicrob. Agents Chemother.,
August 1, 2007;
51(8):
2842 - 2847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. T. Huy, D. T. Uyen, A. Maeda, D. T. X. Trang, T. Oida, S. Harada, and K. Kamei
Simple Colorimetric Inhibition Assay of Heme Crystallization for High-Throughput Screening of Antimalarial Compounds
Antimicrob. Agents Chemother.,
January 1, 2007;
51(1):
350 - 353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Kinobe, R. A. Dercho, J. Z. Vlahakis, J. F. Brien, W. A. Szarek, and K. Nakatsu
Inhibition of the Enzymatic Activity of Heme Oxygenases by Azole-Based Antifungal Drugs
J. Pharmacol. Exp. Ther.,
October 1, 2006;
319(1):
277 - 284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Trivedi, P. Chand, K. Srivastava, S. K. Puri, P. R. Maulik, and U. Bandyopadhyay
Clotrimazole Inhibits Hemoperoxidase of Plasmodium falciparum and Induces Oxidative Stress: PROPOSED ANTIMALARIAL MECHANISM OF CLOTRIMAZOLE
J. Biol. Chem.,
December 16, 2005;
280(50):
41129 - 41136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. T. Huy, S. Serada, D. T. X. Trang, R. Takano, Y. Kondo, K. Kanaori, K. Tajima, S. Hara, and K. Kamei
Neutralization of Toxic Heme by Plasmodium Falciparum Histidine-Rich Protein 2
J. Biochem.,
May 1, 2003;
133(5):
693 - 698.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|